UNSPSC 51124006: Pirmenol hydrochloride

This classification denotes an antimuscarinic agent with the molecular formula C22H30N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JA79OMG4QT, chemically known as 2-pyridinemethanol, alpha-(3-(2,6-dimethyl-1-piperidinyl)propyl)-alpha-phenyl-, monohydrochloride, z-(+-)- but more generally known as pirmenol hydrochloride, which bears US NIH Compound Identifier 65501. European Medicines Agency schedules Pirmenol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03874MIG.

UNSPSC 51124006 Pirmenol hydrochloride, a Commodity code, encompasses advanced cardiovascular medications and other specialized pharmaceutical products that state and local healthcare systems, emergency services, and human services agencies procure for patient care and emergency response. State and local governments buy specific branded or generic drugs under this code to support emergency medical services, hospital formularies, and pharmacy benefit programs. Issuing bodies include city fire-rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across member states and localities. The Tampa Fire Rescue procurement represents the narrower procurement pattern — individual municipalities buying specific medication line items for emergency response — while the Texas HHS RFI and Minnesota MMCAP RFP represent broader, multi-jurisdiction pharmaceutical contracting that encompasses pirmenol and dozens of other drugs as part of statewide or multistate formulary management and cost containment strategies.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications (response deadline April 8, 2026), requesting 1,020 units of Diltiazem and three other cardiac agents for Tampa Fire Rescue with an estimated contract value of $40,000 and a one-year term renewable for two additional years. The Texas Health and Human Services Commission posted RFI HHS0017013 in early April 2026 to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions program, signaling state-level interest in restructuring pharmacy procurement outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP due March 26, 2026 for Generic Multi-Source Pharmaceuticals and OTC Products to establish contracts effective July 1, 2026 across participating state and local government facilities in Minnesota and Oregon, with pricing weighted 75 percent on competitiveness and vendor supply through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson).